Multiple myeloma is a malignant neoplastic disease of the hematological system, mainly caused by malignant proliferation of plasma cells. Its main treatment is the application of systemic chemotherapy. Chemotherapeutic drugs include marfalan, thalidomide, lenalidomide, vincristine, adriamycin and dexamethasone, etc. Among them, pad is one of the chemotherapy regimens, which is often used, including bortezomib, adriamycin and dexamethasone. The most effective regimen for multiple myeloma is the bortezomib-containing regimen. pad regimens are commonly used clinically and do not have significant side effects. It is suitable for systemic chemotherapy for patients with multiple myeloma.